Published in PLoS One on August 22, 2014
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol (2016) 1.08
Evidence linking HHV-6 with multiple sclerosis: an update. Curr Opin Virol (2014) 0.89
Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination. Neurol Neuroimmunol Neuroinflamm (2016) 0.81
Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes. Ann Clin Transl Neurol (2015) 0.76
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Multiple sclerosis. N Engl J Med (2000) 12.69
T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 11.65
Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol (2007) 5.01
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
Myelination in rat brain: method of myelin isolation. J Neurochem (1973) 4.01
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA (2013) 3.65
The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol (2013) 3.13
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol (2010) 3.05
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A (1995) 2.33
Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med (2004) 2.31
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med (2012) 2.14
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06
A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet (2005) 2.03
Autoimmune responses to the brain after stroke are associated with worse outcome. Stroke (2011) 1.95
Death, autoantigen modifications, and tolerance. Arthritis Res (2000) 1.75
The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol (2013) 1.63
Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med (2009) 1.60
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol (2004) 1.56
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest (2001) 1.53
Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol (1991) 1.46
B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest (2012) 1.35
Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun (2009) 1.32
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A (2009) 1.26
Comparison of herpes simplex virus reactivation in ganglia in vivo and in explants demonstrates quantitative and qualitative differences. J Virol (2004) 1.24
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol (2003) 1.16
Epstein-Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry (2005) 1.13
Altered structure of autoantigens during apoptosis. Rheum Dis Clin North Am (2004) 1.09
Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain (2009) 1.09
Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology (2011) 1.08
Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol (2008) 1.05
Frequency of circulating autoreactive T cells committed to myelin determinants in relapsing-remitting multiple sclerosis patients. Clin Immunol (2012) 1.02
Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur J Immunol (1992) 1.01
Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis. J Neurol (2009) 0.98
Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol (2014) 0.92
Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci (1991) 0.90
Peptides of myelin basic protein stimulate T lymphocytes from patients with multiple sclerosis. J Neuroimmunol (1989) 0.90
A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis. J Neuroimmunol (2003) 0.88
Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J Neurol (2005) 0.88
Epstein-Barr virus and multiple sclerosis. Curr Neurol Neurosci Rep (2007) 0.88
Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. Mult Scler (2010) 0.85
Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension. Am J Clin Exp Immunol (2013) 0.84
Low intrathecal immune response of anti-EBNA-1 antibodies and EBV DNA from multiple sclerosis patients. Diagn Microbiol Infect Dis (2011) 0.83
Intrathecal human herpesvirus 6 antibodies in multiple sclerosis and other demyelinating diseases presenting as oligoclonal bands in cerebrospinal fluid. J Neuroimmunol (2011) 0.83
Role of viruses in etiology and pathogenesis of multiple sclerosis. Adv Virus Res (2001) 0.81
The prevalence of human herpesvirus 6 in human sensory ganglia and its co-occurrence with alpha-herpesviruses. J Neurovirol (2007) 0.81
Activation of immune responses to brain antigens after stroke. J Neurochem (2012) 0.80